Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mersana Therapeutics Inc (NASDAQ: MRSN) closed the day trading at $1.31 down -12.08% from the previous closing price of $1.49. In other words, the price has decreased by -$12.08 from its previous closing price. On the day, 1.56 million shares were traded. MRSN stock price reached its highest trading level at $1.495 during the session, while it also had its lowest trading level at $1.25.
Ratios:
For a better understanding of MRSN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 3.83 whereas as Long-Term Debt/Eq ratio is at 2.41.
On February 29, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $2 to $7.
Guggenheim Upgraded its Neutral to Buy on February 29, 2024, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 16 ’24 when Protopapas Anna sold 29,399 shares for $2.71 per share. The transaction valued at 79,671 led to the insider holds 125,153 shares of the business.
MISRA TUSHAR sold 3,357 shares of MRSN for $9,097 on Jan 16 ’24. The SVP, Chief Manuf. Officer now owns 17,966 shares after completing the transaction at $2.71 per share. On Jan 16 ’24, another insider, Mandelia Ashish, who serves as the VP, Chief Accounting Officer of the company, sold 5,025 shares for $2.71 each. As a result, the insider received 13,618 and left with 23,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRSN now has a Market Capitalization of 160704240 and an Enterprise Value of 30895316. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.37 while its Price-to-Book (P/B) ratio in mrq is 19.07. Its current Enterprise Value per Revenue stands at 1.032 whereas that against EBITDA is -0.305.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $6.28, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is -32.50%, while the 200-Day Moving Average is calculated to be -53.16%.
Shares Statistics:
Over the past 3-months, MRSN traded about 1.41M shares per day on average, while over the past 10 days, MRSN traded about 1432450 shares per day. A total of 120.71M shares are outstanding, with a floating share count of 90.27M. Insiders hold about 24.44% of the company’s shares, while institutions hold 68.14% stake in the company. Shares short for MRSN as of 1722384000 were 9113835 with a Short Ratio of 6.48, compared to 1719532800 on 9683738. Therefore, it implies a Short% of Shares Outstanding of 9113835 and a Short% of Float of 9.8000005.
Earnings Estimates
The market rating for Mersana Therapeutics Inc (MRSN) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.15, with high estimates of $0.1 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.25 and -$0.81 for the fiscal current year, implying an average EPS of -$0.66. EPS for the following year is -$0.72, with 8.0 analysts recommending between -$0.44 and -$0.9.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for MRSN’s current fiscal year. The highest revenue estimate was $70M, while the lowest revenue estimate was $11.54M, resulting in an average revenue estimate of $30.18M. In the same quarter a year ago, actual revenue was $36.85M
